Jul 05,2023 TOP STORY

Peer-Reviewed Publication Reports Stanza Preliminary Efficacy Data

Swing Therapeutics announced the publication of the randomized phase II trial (SMART-FM) with Stanza, which appeared this week in The Journal of Behavioral Medicine. This peer-reviewed paper reports clinically significant improvement in well-being and fibromyalgia severity in patients who received an earlier generation of Stanza, Swing Therapeutics’ digital behavioral therapy for fibromyalgia. SMART-FM, a pilot randomized controlled trial, evaluated the impact of the self-guided, smartphone-based digital therapy for patients with fibromyalgia. Sixty-seven patients with fibromyalgia were randomized to receive a prototype version of the Stanza digital therapy or the control, a digital symptom tracking application. At Week 12, 73% of treated participants using the digital therapy reported improvement in well-being (measured by Patient Global Impression of Change) versus 22% of participants in the control arm.

CLINICAL STUDY

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 05,2023

Personalised electronic health programme for recovery after major abdominal surgery: a multicentre, single-blind, randomised, placebo-controlled trial

Despite the adoption of minimally invasive techniques, recovery after abdominal surgery takes a long time. In this study, researchers aimed to assess the impact of a personalised eHealth programme on patients' return to normal activities after major abdominal surgery. Participants in the intervention group had access to a perioperative, personalised eHealth programme consisting of both standard face-to-face care and eHealth, that comprised interactive tools offering goal attainment and a personalised outcome measurement, which managed recovery expectations and provided postoperative guidance tailored to each patient. The control group received standard care and access to a placebo website containing recovery advice provided by the hospital. Results suggest that this eHealth programme, delivering personalised care based on goal attainment scaling, enabled patients to return to their normal activities 13 days earlier than those who received standard care.

CLINICAL STUDY

#mobile app

#telehealth

View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

South Korean researchers use AI to predict immunotherapy side effects

Researchers from various South Korean universities have teamed up to develop an AI model for predicting the side effects of immunotherapy on cancer patients. Korea Advanced Institute of Science and Technology and Asan Medical Center first came up with a comprehensive list of risk factors of the side effects of immuno-oncology drugs based on patients' genomes, transcriptomes, and blood indicators. This was extracted from a large-scale prospective cohort of solid cancer patients, in partnership with nine South Korean medical institutions. From this, a deep learning prediction model was developed that determines whether a patient will show side effects to immunotherapy prior to getting it.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 18,2023

Effects of Customized Digital Health Care Service on Metabolic Syndrome Status and Lifestyle Using a Health Care App: Clinical Trial

Previous studies relating to digital health care demonstrated its effectiveness in managing chronic diseases such as hypertension and diabetes. While many studies have applied digital health care to various diseases, daily health care is needed for healthy individuals before they are diagnosed with a disease. This study aimed to identify the effects of using a customized digital health care service (CDHCS) on risk factors for metabolic syndrome (MS) and lifestyle improvement. The CDHCS used in this study, called Dr Healthing, was developed by the Mediage Research Institute. Dr Healthing provides information regarding the health status of individuals by analyzing the data linked to health checkups from medical institutions and average daily step count data from a Samsung Health app. The population consisted of 63 adults who underwent a health checkup at the National Health Insurance Service Ilsan (NHIS, South Korea) Hospital in 2020.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 26,2023

New Research Demonstrates 2.3 Point Reduction in HbA1c for Dario Digital Health Users with Baseline HbA1c Greater Than 9 points

DarioHealth announced today the presentation of research at the American Diabetes Association 83rd Scientific Sessions demonstrating significant reductions in HbA1c for Dario users compared to non-users. The study was conducted by Sanofi U.S. under its strategic agreement with Dario. The new research presented at the Scientific Sessions used HIPAA-complaint deidentified patient data linking claims, electronic medical record and laboratory results data to construct a study cohort of 568 Dario users and 1,699 matched non-users. The analysis segmented study participants into four bands according to baseline HbA1c and analyzed HbA1c lab results for Dario users against a closely matched population of non-users over a period of six months. The study demonstrated clinically significant differences in reductions in HbA1c for all Dario users compared to non-users, and those users with a baseline HbA1c greater than 9 points demonstrated the greatest improvement with a 2.3 point reduction in HbA1c in Dario users compared to a 1.8 point reduction for non-users.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 22,2023

Incorporating a patient facing application and home calprotectin based patient initiated follow up and monitoring in IBD Home® digital care

The need for directed self-are is fundamental to the safe management of chronic diseases such as IBD, which is characterised by a relapsing and remitting course. Access to timely assessment and modification of treatment is essential during IBD flares to avoid the need for hospitalisation. IBD Home is a whole system model is comprehensive, integrated, and holistic approach to value-based care to provide `multidisciplinary ring` of supported care around the needs of patients where possible in their own homes. Electronic- and virtual-based platforms have been developed to routinely monitor IBD patients and guide appropriate interventions. We incorporated a patient-facing app called MyIBD Care® and CalproSmart™ self-calprotectin test from Ampersand Health in two cohorts of patients participating in IBD Home in the IBD unit at Hull University Teaching Hospitals. The study demonstrated that implementing home-based self-monitoring of faecal calprotectin in IBD patients in long-term remission is not only feasible but also has the potential to reduce the need for in-person appointments.

CLINICAL STUDY

#mobile app

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

TatvaCare to launch clinical trial of COPD DTx

Indian health tech company TatvaCare is launching a clinical trial of its digital therapeutic solution, MyTatva, for people with chronic respiratory disorders. The digital-based solution MyTatva combines personalised care plans, IoT device monitoring, coaching, and counselling services to improve patients' compliance with their care programme. According to a press release, the BREATHE DTx trial seeks to test the efficacy and acceptability of the DTx for COPD and asthma. It will also gauge its capability to reduce exacerbations and incidents. For six months, it will be conducted across eight settings in India and will involve up to 200 participants.

CLINICAL STUDY

#coaching

#connected device

View Analyst & Ambassador Comments
Go to original news
Jun 26,2023

New Research Demonstrates 2.3 Point Reduction in HbA1c for Dario Digital Health Users with Baseline HbA1c Greater Than 9 points

A retrospective cohort study presented at the American Diabetes Association 83rd Scientific Sessions showed that Dario digital health users achieved a 2.3 point reduction in HbA1c for baseline HbA1c greater than 9 points, compared to a 1.8 point reduction with standard care. The new research presented at the Scientific Sessions used HIPAA-complaint deidentified patient data linking claims, electronic medical record and laboratory results data to construct a study cohort of 568 Dario users and 1,699 matched non-users. The analysis segmented study participants into four bands according to baseline HbA1c and analyzed HbA1c lab results for Dario users against a closely matched population of non-users over a period of six months. The study highlights the potential of digital health solutions in improving outcomes for serious diabetes.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 30,2022

Rimidi and Boston Medical Center Release Metrics from Ongoing Remote Monitoring Program for Postpartum Hypertension

Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, and Boston Medical Center, a private, not-for-profit academic medical center in New England, today released metrics from an ongoing remote patient monitoring program for new moms at high-risk of postpartum hypertension. Boston Medical Center leveraged the Rimidi platform to bring remotely-generated patient data from cellular-connected blood pressure cuffs into their clinical workflow. As part of Epic’s app orchard, Rimidi launches directly within the BMC team’s Epic experience. Resulting from the initial success of Boston Medical Center’s postpartum hypertension program, the center is now expanding the program to include monitoring for gestational hypertension, using cellular blood pressure cuffs and gestational diabetes, using cellular glucometers and FreeStyle Libre Continuous Glucose Monitors.

CLINICAL STUDY

#rpm

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

American Diabetes Association to Highlight Innovations in Diabetic Eye Condition

Another study presented at the ADA conference in San Diego, CA highlighted the use of AI to diagnose diabetic retinopathy. The study, Identifying the Risk of Diabetic Retinopathy (DR) Progression Using Machine Learning on Ultrawide Field Retinal Images, examined the use of AI algorithms to improve the process of estimating the risk of DR progression. In this study, the authors developed and validated machine learning (ML) models for DR progression from ultrawide field (UWF) retinal images, which were labeled for baseline DR severity and progression. Findings show the AI prediction for 91% of the images were either correct labels or were the labels with greater progression than the original labels.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY